Xinkang Medical: Pioneering Digital Therapeutics in Mental Health with Solutions Deployed Across 300+ Institutions

In recent years, public and market attention to mental health has continued to rise.

On one hand, rising economic standards and growing public awareness of physical and mental well-being have awakened the “dormant” demand for mental health services. On the other hand, policy support—ranging from the issuance of documents such as the Specifications for the Management and Treatment of Mental Disorders and the Guiding Opinions on Mental Health Services, to the significant emphasis placed on mental health and psychiatric hygiene in the 14th Five-Year Plan and the Healthy China Action (2019–2030)—demonstrates the state’s commitment to improving the psychological well-being of its citizens.

Driven by multiple factors, a market sector valued at hundreds of billions of yuan has emerged, attracting significant capital investment. According to incomplete statistics from VCBeat, 14 companies in China’s mental health and psychological wellness sector completed 17 financing rounds over the past year, marking a substantial increase compared with previous years.

Despite the booming market, the mental health industry has long grappled with issues such as supply-demand imbalances and the inefficiencies and significant limitations inherent in traditional diagnostic and treatment methods. To address these challenges, numerous companies are leveraging their respective strengths to continuously roll out innovative solutions. As a player in the field, Xinkang Medicine is no exception.

Xinkang Medicine, established in 2020, is an innovative enterprise dedicated to the fields of mental health and brain science. Since its inception, Xinkang Medicine has been committed to technology-driven innovation, actively exploring digital medical technologies for psychological diagnosis and treatment. The company has successively launched diagnostic and therapeutic product solutions in areas such as psychiatry and psychology, sleep medicine, maternal mental health, and cognitive rehabilitation, safeguarding public mental health through digital diagnostic and treatment approaches.

Mental Health Sector: How Large Is the Demand in This Market Derived from Psychological Needs?

Perhaps this set of data can provide the answer.

According to data from the White Paper on Mental Health of Urban Residents in China, 73.6% of urban residents are currently in a state of suboptimal psychological health, while 16.1% exhibit varying degrees of psychological issues. This highlights the substantial demand within the mental health market.

Despite the enormous demand, China’s mental health industry continues to face multifaceted challenges, with insufficient mental health service resources standing as a major obstacle.

As of the end of 2020, China had more than 50,000 licensed (assistant) psychiatrists, fewer than 5,000 psychotherapists engaged in mental health work in medical and health institutions, and 40,000 psychological counselors; by comparison, the global average was 4 psychiatrists and 13 nurses per 100,000 population.

Amidst the shortage of specialized professionals and the growing number of patients, how can technology address these challenges in an environment where demand and talent supply are not fully aligned? XinKang Medicine has proposed corresponding solutions.

In the treatment of psychiatric and psychological disorders, pharmacotherapy has traditionally been the mainstay. In recent years, non-pharmacological therapies have also developed rapidly, with an increasing number of healthcare professionals gradually implementing non-pharmacological physical interventions such as transcranial magnetic stimulation (TMS), non-pharmacological psychotherapeutic approaches including cognitive behavioral therapy (CBT), and emerging non-pharmacological modalities incorporating virtual reality (VR) technology.

Among these, psychotherapeutic techniques—whether classic cognitive behavioral therapy or cognitive remediation therapy (CRT), which targets the rehabilitation of patients’ long-term cognitive function—possess irreplaceable advantages, including broad applicability, absence of side effects, and favorable long-term efficacy.

At present, the non-pharmacological physical diagnosis and treatment sector features a rich array of brands, whereas there is still a shortage of specialized brands in non-pharmacological psychological diagnosis and treatment. Given the high degree of alignment between digital healthcare application scenarios and the non-pharmacological psychological diagnosis and treatment system, exploring digital approaches to psychological diagnosis and treatment has emerged as a highly feasible direction.

The essence of digital healthcare lies in being software-driven and grounded in evidence-based medicine, applying computerized and standardized therapeutic methods and processes to clinical practice to achieve the goals of disease prevention, treatment, and management. The efficiency and standardization of digital healthcare can address the limitations of traditional psychotherapy, which relies entirely on manual delivery throughout the entire process, thereby significantly improving clinical efficiency and alleviating, to some extent, the current shortage of professional personnel.

In China, although a number of companies have emerged that promote digital therapeutics in the field of mental health, their treatment technologies and scenario deployments remain relatively limited.

Xinkang Medicine is undoubtedly a leader and a rising star. Its innovative, multi-technological digital therapeutics for mental health integrate technological innovation with traditional manual psychological interventions, creating a comprehensive digital solution for psychological diagnosis and treatment, and injecting new vitality into the mental health industry.

Compared with traditional services, digital therapeutics offer advantages such as replicability, scalability, lower costs, and more convenient accessibility.

Xinkang Medicine’s deep cultivation in this field is closely tied to the background of its founding team.

Tan Jun, founder of Xinkang Medicine, is a graduate of Peking University and serves as a member of the Committee on Psychological Standards and Services Research under the Chinese Psychological Society. He co-established the Special Fund for Diagnosis and Treatment Research in Mental Psychology and Cognitive Disorders. As a high-level talent introduced by the Qingkong Innovation Base, he co-founded “Shanxi Bode Technology Co., Ltd.” and secured financing from the Tsinghua Holdings Sci-Tech Innovation Fund.

Tan Jun, Founder of Xinkang Medicine

In 2020, Tan Jun founded Xinkang Medical, established a core R&D team focused on digital healthcare software, and recruited senior marketing professionals with extensive experience in the mental health sector, years of management experience at publicly listed companies, and forward-thinking strategic vision.

Years of in-depth engagement with the healthcare industry have equipped the founder and core team members of Xinkang Medicine with specialized academic backgrounds and a keen sense for scientific research. Xinkang Medicine maintains deep collaborations with institutions such as the Chinese Psychological Society, the Institute of Psychology of the Chinese Academy of Sciences, the Wu Jieping Medical Foundation, and the Oklahoma Medical Research Foundation in the United States, thereby establishing a comprehensive industry-academia-research cooperation system.

Xinkang Medical has achieved comprehensive synergy across technology, disciplinary expertise, and marketing. By leveraging precise market positioning and resource integration, the company has strategically launched more than ten independently developed digital therapeutics products, secured multiple patents, met market demands, and rapidly enhanced its brand reputation.

Since its establishment, Xinkang Medicine has launched multiple digital therapeutic products focused on four key areas: mental health, sleep medicine, maternal psychological care, and cognitive rehabilitation. Functionally, these products are categorized into assessment tools and intervention solutions. The assessment portfolio includes the Psychological CT System and the Psychological Health Examination System. The intervention portfolio comprises the Computerized Cognitive Behavioral Therapy (CCBT) System, the Cognitive Behavioral Therapy for Insomnia (CBT-I) System, the Virtual Reality (VR) Psychological Assessment and Treatment System, and the Cognitive Checkup and Rehabilitation Training (CCRT) Software for cognitive impairments.

In terms of market expansion, Xinkang Medicine chose to focus first on the traditional healthcare market, and rapidly penetrated the market by continuously enhancing its professional influence and brand awareness through scientific research collaborations with specialized institutions. By the end of 2021, Xinkang Medicine’s products had been adopted by more than 300 hospitals.

During its development, to enhance the convenience of its products and services, Xinkang Medicine began gradually transitioning its original service model from offline-only to a hybrid online-offline model. Leveraging standardized full-scenario psychological assessments, Cognitive Behavioral Therapy (CBT), immersive Virtual Reality (VR) psychotherapy, and Cognitive Remediation Therapy (CRT), it provides the market with a comprehensive, closed-loop solution. This solution-oriented marketing model has gained recognition from B-end end users and distribution channels, thereby generating substantial market stickiness.

The digital diagnosis and treatment service platform for mental and psychological health, developed by Xinkang Medical Planning, not only covers online psychiatric and psychological diagnostic and therapeutic services but also includes self-intervention and rehabilitation solutions tailored for individual consumers.

For B-side medical institutions and physicians, this platform not only enables effective patient diagnosis and treatment across a wider range of scenarios but also facilitates long-term prognostic follow-up and the formulation of personalized treatment plans, thereby achieving superior intervention outcomes.

For C-end users, the digital diagnosis and treatment plans generated by this platform can significantly reduce the cost of accessing professional medical services. Furthermore, given the strong transferability of digital therapeutics technology, the platform provides sufficient autonomy to facilitate the repeated consolidation of therapeutic effects. These features represent a critical step toward further deepening technical services and expanding into mobile self-healing solutions in the future.

Overall, Xinkang Medicine has established a comprehensive B2B2C diagnostic and treatment service framework by integrating its internet-based psychiatric and psychological diagnosis and treatment platform with a consumer-facing self-healing platform.

As digital therapeutics continue to gain market recognition, Xinkang Medicine is also continuously exploring new service systems based on its own development. Looking to the future, Xinkang Medicine is also steadily expanding its strategic layout in the field of digital therapeutics.

Xinkang Medicine has now planned to advance the NMPA registration and approval processes for multiple products under its portfolio, while simultaneously accelerating the digitalization of more diagnostic and therapeutic products, thereby delivering broader and more comprehensive digital therapeutics solutions to the public.

Meanwhile, Xinkang Medicine maintains close and active collaborations with professional institutions such as the China National Institute of Standardization and the Chinese Psychological Society, to facilitate the establishment of general specifications for internet-based psychological services and technologies, jointly promoting the development of industry standards and sector growth.

Xinkang Medicine will continue to optimize its product portfolio, increase market investment, and simultaneously enhance service quality for B-end medical institutions while strengthening C-end market expansion and user engagement, thereby making high-quality mental health services accessible to a broader population. Upholding its corporate mission of “Promoting Better Mental Health for the People,” Xinkang Medicine is committed to safeguarding the psychological well-being of the nation.